Dupixent shows potential as a treatment for atopic dermatitis, alopecia and vitiligo, targeting shared immune pathways for ...

Children with moderate/more extensive atopic dermatitis treated with ruxolitinib cream achieved significant disease control ...

A larger thymus size at 2 months of age is linked to an increased likelihood of having atopic dermatitis within the first 2 ...

Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, ...

If you experience chronic dry, itchy and red skin, you may be one of the millions of Americans with eczema. The National Eczema Association reports that an estimated 10% of the world ...

Integrative approaches targeting neurological and immune pathways may help break the itch–scratch cycle in atopic dermatitis, improving pruritus, stress, sleep, and patient outcomes.

For patients with skin of color and atopic dermatitis (AD), lebrikizumab is efficacious and safe, according to a study ...

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Chronic spontaneous urticaria places a heavier burden on patients than atopic dermatitis and psoriasis, leading to a worse ...

Patients with moderate to severe and severe alopecia areata have a greater burden of comorbid atopic dermatitis than those with mild alopecia areata.

A real-world study of atopic dermatitis patients highlights the feasibility of current treat-to-target goals while suggesting ...

Get insights on Corvus Pharmaceuticals' Q2 2025 earnings call. Learn about soquelitinib's clinical progress, Phase II trial plans, and financial strategies.